Kopp HG - Search Results

1

The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma.

Kropp KN, Maurer S, Rothfelder K, Schmied BJ, Clar KL, Schmidt M, Strunz B, Kopp HG, Steinle A, Grünebach F, Rittig SM, Salih HR, Dörfel D. Kropp KN, et al. Among authors: kopp hg. Cancer Immunol Immunother. 2018 Jun;67(6):935-947. doi: 10.1007/s00262-018-2151-y. Epub 2018 Mar 19. Cancer Immunol Immunother. 2018. PMID: 29556699 Free PMC article.

2

GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity.

Placke T, Salih HR, Kopp HG. Placke T, et al. Among authors: kopp hg. J Immunol. 2012 Jul 1;189(1):154-60. doi: 10.4049/jimmunol.1103194. Epub 2012 May 30. J Immunol. 2012. PMID: 22649191 Free article.

3

The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells.

Dörfel D, Lechner CJ, Joas S, Funk T, Gutknecht M, Salih J, Geiger J, Kropp KN, Maurer S, Müller MR, Kopp HG, Salih HR, Grünebach F, Rittig SM. Dörfel D, et al. Among authors: kopp hg. Cancer Immunol Immunother. 2018 May;67(5):775-783. doi: 10.1007/s00262-018-2129-9. Epub 2018 Feb 21. Cancer Immunol Immunother. 2018. PMID: 29468363 Free PMC article.

4

Modulation of natural killer cell anti-tumor reactivity by platelets.

Placke T, Kopp HG, Salih HR. Placke T, et al. Among authors: kopp hg. J Innate Immun. 2011;3(4):374-82. doi: 10.1159/000323936. Epub 2011 Mar 12. J Innate Immun. 2011. PMID: 21411974 Free article. Review.

5

Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells.

Placke T, Örgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, Salih HR. Placke T, et al. Among authors: kopp hg. Cancer Res. 2012 Jan 15;72(2):440-8. doi: 10.1158/0008-5472.CAN-11-1872. Epub 2011 Nov 29. Cancer Res. 2012. PMID: 22127925

6

Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells.

Maurer S, Kropp KN, Klein G, Steinle A, Haen SP, Walz JS, Hinterleitner C, Märklin M, Kopp HG, Salih HR. Maurer S, et al. Among authors: kopp hg. Oncoimmunology. 2017 Nov 27;7(2):e1364827. doi: 10.1080/2162402X.2017.1364827. eCollection 2018. Oncoimmunology. 2017. PMID: 29308299 Free PMC article.

7

Modulation of Immune Responses by Platelet-Derived ADAM10.

Maurer S, Kopp HG, Salih HR, Kropp KN. Maurer S, et al. Among authors: kopp hg. Front Immunol. 2020 Feb 5;11:44. doi: 10.3389/fimmu.2020.00044. eCollection 2020. Front Immunol. 2020. PMID: 32117229 Free PMC article. Review.

8

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas.

Hagelstein I, Lutz MS, Schmidt M, Heitmann JS, Malenke E, Zhou Y, Clar KL, Kopp HG, Jung G, Salih HR, Märklin M, Hinterleitner C. Hagelstein I, et al. Among authors: kopp hg. Front Immunol. 2021 Apr 14;12:653081. doi: 10.3389/fimmu.2021.653081. eCollection 2021. Front Immunol. 2021. PMID: 33936075 Free PMC article.

9

Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity.

Kopp HG, Placke T, Salih HR. Kopp HG, et al. Cancer Res. 2009 Oct 1;69(19):7775-83. doi: 10.1158/0008-5472.CAN-09-2123. Epub 2009 Sep 8. Cancer Res. 2009. PMID: 19738039

10

Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation.

Placke T, Kopp HG, Salih HR. Placke T, et al. Among authors: kopp hg. Clin Dev Immunol. 2010;2010:239083. doi: 10.1155/2010/239083. Epub 2010 Sep 26. Clin Dev Immunol. 2010. PMID: 20936139 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

137 results

Search Page